Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.
Bagatell
Rochelle
R
Steele Memorial Children's Research Center and The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA. bagatell@peds.arizona.edu
Beliakoff
Jason
J
David
Cynthia L
CL
Marron
Marilyn T
MT
Whitesell
Luke
L
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D016227:Benzoquinones; D001859:Bone Neoplasms / Q000473:pathology*; D049109:Cell Proliferation; D002470:Cell Survival; D002648:Child; D002945:Cisplatin / Q000494:pharmacology*; D004249:DNA Damage; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D015151:Immunoblotting; D020287:In Situ Nick-End Labeling; D047029:Lactams, Macrocyclic; D009447:Neuroblastoma / Q000473:pathology*; D012516:Osteosarcoma / Q000473:pathology*; D011809:Quinones / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D011809:Quinones; D002945:Cisplatin; C001277:geldanamycin